Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 19, Issue 2, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2023.2221146
Keywords
SARS-CoV-2; COVID-19; inactivated vaccine; effectiveness; efficacy; meta-analysis
Categories
Ask authors/readers for more resources
This study aimed to evaluate the effectiveness of heterologous or homologous COVID-19 vaccine regimens after the primary immunization with CoronaVac or Sinopharm vaccines. The results showed that both heterologous and homologous booster significantly improved the effectiveness against COVID-19 infection. The effectiveness ranged from 51.48% for two doses of inactivated vaccine to 89.19% for heterologous mRNA vaccine booster. Further evidence is still needed to confirm these findings.
We aimed to evaluate the effectiveness or efficacy of heterologous or homologous COVID-19 vaccine regimens against COVID-19-related outcomes after primary immunization with two doses of CoronaVac or Sinopharm COVID-19 vaccines. PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched up to 31 October 2022. The primary measure was vaccine effectiveness against COVID-19 infection with homologous or heterologous booster. The results showed heterologous and homologous booster significantly improved effectiveness against COVID-19 infection compared to primary immunization. The effectiveness against COVID-19 infection was 89.19% (95%CI 78.49, 99.89) for heterologous mRNA vaccine booster, 87.00% (95%CI 82.14, 91.85) for non-replicating vector vaccine booster, 69.99% (95%CI 52.16, 87.82) for homologous booster, and 51.48% (95%CI 41.75, 61.21) for two doses of inactivated vaccine. Homologous and heterologous regimens were also effective against SARS-CoV-2 variants, and more evidence is still needed to confirm our findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available